UroGen Pharma Ltd. Human Resources Contracts & Agreements
27 Contracts & Agreements
- Bonus & Incentive Agreements (11 contracts)
- Compensation Agreements (1)
- Employment Agreements (11)
- Separation Agreements (4)
- Amendment to Form of Restricted Stock Unit Grant Notice under the UroGen Pharma Ltd. 2017 Equity Incentive Plan (Filed With SEC on March 14, 2024)
- Performance-Based Restricted Stock Unit Grant Notice by and between the Registrant and Elizabeth Barrett, dated as of November 13, 2023 (Filed With SEC on November 14, 2023)
- Form of Performance-Based Restricted Stock Unit Grant Notice and Performance-Based Restricted Stock Unit Award Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan (Filed With SEC on November 14, 2023)
- Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan (Filed With SEC on November 14, 2023)
- Form of Stock Option Grant Notice and Stock Option Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan (Filed With SEC on November 14, 2023)
- 2017 Equity Incentive Plan, as amended (Filed With SEC on November 14, 2023)
- Amended and Restated Compensation Policy for Officer Holders (Filed With SEC on March 24, 2023)
- 2017 Equity Incentive Plan, as amended (Filed With SEC on March 24, 2023)
- UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (Filed With SEC on June 13, 2022)
- Employment Agreement between the Company and Dong Kim, dated March 20, 2022 (Filed With SEC on March 21, 2022)
- UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (Filed With SEC on June 8, 2021)
- Amendment 2 to Employment Agreement between the Company and Mark Schoenberg, dated March 15, 2021 (Filed With SEC on May 13, 2021)
- Amendment 1 to Employment Agreement between the Company and Jason Smith, dated January 26, 2021 (Filed With SEC on May 13, 2021)
- Amendment 1 to Employment Agreement between the Company and Mark Schoenberg, dated January 26, 2021 (Filed With SEC on May 13, 2021)
- Amendment 1 to Employment Agreement between the Company and Elizabeth Barrett, dated January 26, 2021 (Filed With SEC on May 13, 2021)
- Employment Agreement between the Company and Jason Smith, dated August 12, 2020 (Filed With SEC on November 9, 2020)
- Employment Agreement between the Company and Molly Henderson, dated September 3, 2020 (Filed With SEC on September 9, 2020)
- Separation Agreement between the Company and Peter Pfreundschuh, dated September 8, 2020 (Filed With SEC on September 9, 2020)
- UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (Filed With SEC on June 10, 2020)
- Separation Agreement between the Company and Stephen Mullennix, dated March 20, 2020 (Filed With SEC on March 23, 2020)
- Separation and Agreement between the Company and Gary Titus, dated as of July 11, 2018 (Filed With SEC on February 28, 2019)
- Separation and Release Agreement between the Registrant and Ron Bentsur, dated as of January 3, 2019 (Filed With SEC on February 28, 2019)
- Employment Agreement by and between the Registrant and Mark Schoenberg, dated as of December 5, 2017 (Filed With SEC on February 28, 2019)
- Employment Agreement by and between the Registrant and Stephen Mullennix, dated as of January 17, 2018 (Filed With SEC on February 28, 2019)
- Employment Agreement by and between the Registrant and Peter Pfreundschuh, dated as of July 31, 2018 (Filed With SEC on February 28, 2019)
- Employment Agreement by and between the Registrant and Elizabeth Barrett, dated as of January 3, 2019 (Filed With SEC on February 28, 2019)
- 2017 Equity Incentive Plan, as amended (Filed With SEC on February 28, 2019)